Skip to main content

FIBROGEN INC

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

KYNB$3.90+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Exhibit · Incorporation By Reference
NumberExhibit DescriptionFormSEC File No.ExhibitFiling Date
3.1Amended and Restated Certificate of Incorporation of FibroGen, Inc.8-K001-367403.111/21/2014
3.2Amended and Restated Bylaws of FibroGen, Inc.8-K001-367403.104/04/2025
3.3Certificate of Amendment of the Amended and Restated Certificate of Incorporation of FibroGen, Inc.8-K001-367403.106/12/2025
4.1Form of Common Stock Certificate.8-K001-367404.111/21/2014
4.2Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014.S-1/A333-1990694.1710/24/2014
10.1* †Amendment No.2 to the Collaboration Agreement by and between Astellas Pharma, Inc. and FibroGen, Inc., dated as of June 6, 2025.————
10.2Second Amendment to Financing Agreement, by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of June 5, 2025.8-K001-3674010.106/09/2025
10.3Third Amendment to Financing Agreement, by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of July 14, 2025.8-K001-3674010.107/14/2025
31.1*Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).————
31.2*Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).————
32.1*Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1)).————
101.INSInline XBRL Instance Document: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.————
101.SCHInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.————
104Cover Page formatted as inline XBRL and contained in Exhibits 101.————
  • Filed herewith.

† Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential.

  • Indicates a management contract or compensatory plan.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.